Horien Biotech (7814) was transferred from
the Emerging Stock Market to the OTC Market today (16th). With its overseas
expansion and new product development continuing, analysts are optimistic about
the company's sustained growth momentum.
Horien Biotech stated that its June revenue
increased by 209.29% year-on-year, benefiting from increased demand in Taiwan,
the United States, and overseas markets. Regarding its overseas expansion, the
company obtained three Class 4 medical device marketing authorizations in
Thailand in July, and Class III medical device licenses in the Philippines and
Vietnam are expected to be obtained soon, strengthening its presence in the
Southeast Asian market. Furthermore, its bio-ink products are expected to be exported
to the European market by the end of the year.
In terms of R&D, Horien Biotech's
independently developed biodegradable ureteral stent has obtained a Taiwanese
invention patent and plans to apply for patents in the United States, Europe,
and China. Currently, sample development has been completed and the product has
entered the animal testing phase. The company pointed out that the product is
expected to improve the problem of traditional ureteral stents requiring a
second surgery for removal. In addition, collagen regeneration patches
developed using decellularization technology have entered the trial production
stage, targeting the surgical and orthopedic tissue repair market.
Regarding supply chain development, its
subsidiary, Shengli Biotechnology, has signed memorandums of understanding and
cooperation agreements with Taiwan Sugar Corporation and Taiwan Livestock
Corporation to establish a supply chain for animal-derived raw materials for
medical devices that complies with ISO 13485 and ISO 22442 standards, ensuring
the supply of high-end collagen medical device raw materials.
Chairman Tsai Kuo-Tien stated that listing
on the OTC market is a significant milestone for the company. Moving forward,
the company will continue to deepen its existing markets in dentistry and
surgery, and promote the development of high-end medical device products and overseas
markets. With the acquisition of international certifications and the progress
of new product development, the company expects to drive medium- to long-term
operational growth.
Report Link:
Horien Biotech Lists on the
OTC Market Today; Certification Obtained in Thailand, Bio-inks Expand into
Europe, Aiming for Overseas Growth
Mnews
